267 related articles for article (PubMed ID: 25870161)
1. Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Eikelboom JW; Bosch J
Evid Based Med; 2015 Jun; 20(3):117. PubMed ID: 25870161
[No Abstract] [Full Text] [Related]
2. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
[TBL] [Abstract][Full Text] [Related]
3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
5. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
9. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
10. [Expectation to and problems of thrombin inhibitor].
Uchiyama S
Rinsho Shinkeigaku; 2011 Nov; 51(11):1004-6. PubMed ID: 22277458
[TBL] [Abstract][Full Text] [Related]
11. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
[TBL] [Abstract][Full Text] [Related]
12. Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Aalbers J; Hardy G
Cardiovasc J Afr; 2012 Jul; 23(6):350-1. PubMed ID: 23091827
[No Abstract] [Full Text] [Related]
13. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Rosenzweig M; Lane DA; Lip GY
Am J Med; 2014 Apr; 127(4):329-336.e4. PubMed ID: 24361757
[TBL] [Abstract][Full Text] [Related]
14. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Zotova IV; Zateĭshchikov DA
Kardiologiia; 2014; 54(2):79-85. PubMed ID: 24888206
[No Abstract] [Full Text] [Related]
15. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Marín F; Roldán V; Lip GY
Expert Opin Pharmacother; 2012 Jun; 13(8):1087-90. PubMed ID: 22568622
[No Abstract] [Full Text] [Related]
16. Use of dabigatran to prevent stroke in patients with atrial fibrillation.
Mooney T
Nurs Stand; 2013 Mar 6-12; 27(27):35-41. PubMed ID: 23556305
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Messori A; Fadda V; Maratea D; Trippoli S
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):683-5. PubMed ID: 23032961
[No Abstract] [Full Text] [Related]
[Next] [New Search]